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Abstract
Background Bariatric surgery is considered the most
effective treatment for reducing excess body weight and
maintaining weight loss (WL) in severely obese patients.
There are limited data evaluating metabolic and body
composition changes after different treatments in type III
obese (body mass index [BMI]>40 kg/m2).
Methods Twenty patients (9 males, 11 females; 37.6±
8 years; BMI=50.1±8 kg/m2) treated with dietary therapy
and lifestyle correction (group 1) have been compared with
20 matched patients (41.8±6 years; BMI=50.4±6 kg/m2)
treated with laparoscopic gastric bypass (LGBP; group 2).
Patients have been evaluated before treatment and
after >10% WL obtained on average 6 weeks after LGBP
and 30 weeks after integrated medical treatment. Metabolic
syndrome (MS) was evaluated using the Adult Treatment
Panel III/America Heart Association (ATP III/AHA) criteria.
Resting metabolic rate (RMR) and respiratory quotient (RQ)
was assessed with indirect calorimetry; body composition
with bioimpedance analysis.
Results At entry, RMR/fat-free mass (FFM) was 34.2±7 kcal/
24 h·kg in group 1 and 35.1±8 kcal/24 h·kg in group 2 and
did not decrease in both groups after 10% WL (31.8±6 vs
34.0±6). Percent FFM and fat mass (FM) was 50.7±7% and
49.3±7% in group 1 and 52.1±6% and 47.9±6% in group 2,
respectively (p=n.s.). After WL, body composition signifi-
cantly changed only in group 1 (% FFM increased to 55.9±6
and % FM decreased to 44.1±6; p=0.002).
Conclusion After >10% WL, MS prevalence decreases
precociously in surgically treated patients; some improve-
ments in body composition are observed in nonsurgically
treated patients only. Further investigations are needed to
evaluate long-term effects of bariatric surgery on body
composition and RMR after stable WL.
Keywords Type III obesity . Laparoscopic gastric bypass .
Body composition . Resting metabolic rate .Weight loss
Introduction
Severe obesity, corresponding to a body mass index
(BMI) ≥40 kg/m2, is a major health hazard that has not
yet been fully recognized by health professionals and health
sciences in western societies. A recent US survey shows
that severe obesity affects more than 4% of the whole adult
population; this prevalence has more than doubled in the
last 20 years and is still on the rise [1]. On the other hand,
there are epidemiological data confirming that some
comorbidities, such as the metabolic syndrome (MS), are
present in over 20% of the adult population. A similar
figure for nonalcoholic fatty liver disease (NAFLD) has
been reported [2, 3]. Both reach a very high prevalence in
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severe obesity: about 60% in men and 55% in women for
MS, as reported previously also by our group [4], and 90%
in NAFLD [5], respectively.
The best way to significantly decrease the obesity
prevalence is prevention. However, whereas this remains
the key long-term winning strategy, obesity requires a
variety of treatment options based on individual and group
intervention. The aims of treatment for obesity are main-
taining long-term weight loss (WL), and improving
comorbidities and quality of life.
However, severely obese individuals have limited
options. Behavioral therapies for reducing energy intake,
improving eating behaviors, and increasing physical activ-
ity—associated with pharmacotherapy—generally achieve
only modest and transient effects [6, 7].
In particular, although it is generally agreed that
nonsurgical treatments do not solve the problem of severe
obesity, there is little doubt that a well-constructed and
supervised medical program can help many people achieve
a substantial WL. Nevertheless, bariatric surgery actually
represents the most effective therapeutic option for reducing
excess weight and maintaining WL in patients with
clinically severe obesity.
The ideal goal of any weight reduction therapy in obesity
is to obtain and maintain a reduction of fat mass (FM)
without inducing a significant loss of fat-free mass (FFM)
[8]. Maintenance of FFM during WL is considered crucial
to preserve skeletal integrity and functional capacities [9].
Moreover, the reduction in resting energy expenditure
associated with a loss of FFM may contribute to the difficulty
in maintaining body weight often observed in obese subjects
after a period of negative energy balance [8, 10].
There are limited data evaluating metabolic and body
composition changes comparing medical vs surgical different
treatments in type III obese patients (BMI>40 kg/m2) [11].
The aim of this study was to compare metabolic and
nutritional status (body composition and resting energy
expenditure) changes in severely obese patients after 10%
WL achieved by laparoscopic bariatric surgery or by
integrated medical treatment that included hypocaloric diet
and lifestyle correction.
Methods
Forty adult patients (18 males [M], 22 females [F]; age
range 18–50 years) consecutively attending the outpatient
Clinic for Severe Obesity of the Federico II University
Hospital in Naples were enrolled in a clinical protocol that
had been approved by the local ethical committee.
Twenty patients (9 M, 11 F; age 37.6±8.5 years; BMI=
50.1±8.5 kg/m2) successful treated with dietary and
lifestyle correction (group 1) were retrospectively compared
with 20 age-, sex-, and BMI-matched patients (9 M, 11 F;
41.8±6.3 years; BMI=50.4±6.5 kg/m2) treated with lapa-
roscopic bariatric surgery (group 2). All patients were
selected among those regularly attending the clinic and
evaluated before treatment and after achieving about 10%
WL, on average 6 weeks after bariatric surgery and at
30 weeks after integrated medical treatment.
At entry, all patients underwent a clinical examination to
determine the presence and severity of associated medical
conditions. Dietary history, food habits, and previous WL
efforts were accurately evaluated by means of an interview.
Anthropometry
Initial assessment included anthropometric measurements
by means of standard procedures: height was measured to
the nearest 0.1 cm with a stadiometer and body weight was
measured to the nearest 0.1 kg on a balance beam scale
with the subject barefoot and wearing only light undergar-
ment; height and weight were recorded and BMI (kg/m2)
calculated; waist circumference was assessed with a tape
measure at the iliac crests.
Hematobiochemical Examination
All patients underwent a routine hematobiochemical exam-
ination including: total and high-density lipoprotein cho-
lesterol (HDL-C), triglyceride (TG), glucose and insulin,
alanine aminotransferase (ALT), aspartate aminotransferase
(AST), gamma-glutamyltrasferase (GGT), alkaline phosfa-
tase (AP), total bilirubin (T-Bil), hemoglobin (Hb), and total
red blood cell count. All analytes were detected using
current hematochemical kits.
Metabolic Syndrome
Blood pressure was measured on the right arm after the
patient had sit for at least 5 min; a standard sphygmoma-
nometer and adequately sized cuff were used. The diagnosis
of high blood pressure was made when values were >130/
85 mmHg. Hypercholesterolemia, hypertriglyceridemia,
and low HDL-cholesterolemia were diagnosed when values
were over 200 mg/dl, 150 mg/dl, and below 40 mg/dl in
men and <50 mg/dl in women, respectively. These cutoff
points were chosen according to the Adult Treatment Panel
III (ATP III) and the American Heart Association (AHA)
criteria to identify MS. The cutoff points for waist
circumference were 102 cm in men and 88 cm in women
according to the ATP III and 94 cm in men and 82 cm in
women according to the AHA.
The cutoff points for glycemia were ≥110 mg/dl
according to the ATP III and ≥100 mg/dl according to the
AHA. The prevalence of MS was determined considering
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the combination of three out of five risk factors as described
elsewhere [12].
Homeostasis model assessment (HOMA), based on
serum fasting glucose (mmol/l)×insulin levels (μU/l)/
22.5, was also used as an index of insulin resistance. MS
was evaluated using both ATP III and AHA criteria.
Fatty Liver Index
The risk to have hepatic steatosis was evaluated with the
Fatty Liver Index (FLI), an algorithm based on BMI, waist
circumference, triglycerides, and GGT, as previously
described by other authors [13].
Single-frequency Bioimpedance Analysis
Body composition was assessed by bioimpedance analysis
(BIA). Single-frequency BIA was carried out by the same
operator using a BIA 101 device (injection of an alternating
current at 800 μA and 50 kHz) (RJL/Akern System,
Florence, Italy). Measurements were performed on the
nondominant side of the body at an ambient temperature of
22–24°C after voiding and after being in the supine position
for 20 min. A standard tetrapolar technique was used,
placing the measuring electrodes on the anterior surface of
the wrist and ankle, and the injecting electrodes on the
dorsal surface of the hand and foot. The BIA variables
considered were resistance (R), reactance (Xc), and phase
angle (PhA). The bioimpedance index (BI) was calculated
as the ratio height2/resistance (cm2 Ω−1). The instrument
was routinely checked with resistors and capacitors of
known values.
Indirect Calorimetry
Resting metabolic rate (RMR) was measured by indirect
calorimetry using a canopy system (V max 29 N, Sensor
Medics, Anaheim, USA) in a quiet environment and with
patients in the supine position for 30 min before measure-
ment. After a 15- to 20-min adaptation period to the
instrument, oxygen consumption and carbon dioxide
production were determined for 45 min. Energy expendi-
ture was derived from CO2 production and O2 consumption
with the appropriate Weir’s formula neglecting protein
oxidation. The apparatus was calibrated with gas mixtures
of known composition before each test and regularly
checked by burning ethanol.
Integrated Medical Treatment: Group 1
Twenty patients (9 M, 11 F; age 37.6±8.5 years; BMI=
50.1±8.5 kg/m2) underwent psychiatric consultation fol-
lowed by diet therapy and lifestyle correction (group 1).
At the first visit, all patients were instructed by the
dietician on how to fill in their food and activity diaries.
After a week, they were given a low calorie diet, which was
tailored to each patient’s resting energy expenditure, food
and activity diary, and metabolic data.
The patients were instructed to gradually increase their
physical activity by walking outdoors up to 30 min a day.
Each patient was seen on a biweekly basis. All patients
were studied at entry and after achieving >10% WL, as a
mean 30 weeks after starting the integrated medical
treatment.
Bariatric Surgery: Group 2
Twenty patients, gender-, age-, and BMI-matched with
group 1 (41.8±6.3 years; BMI=50.4±6.5 kg/m2), were
selected for Roux-en-Y gastric bypass (RYGBP) (group 2).
All patients were reviewed weekly by the doctor and the
dietician for evaluation of symptoms and careful dietary
monitoring and supplementation. Patients were encouraged
to start physical activity sessions, particularly walking
30 min a day.
All patients underwent a comprehensive preoperative
and postoperative psychiatric evaluation conducted by a
behaviorist with expertise in bariatric patient management.
This assessment included personal and social history,
history of psychiatric problems, current living situation,
and support system. None of the participants had any
evidence of psychiatric diseases.
All patients were studied at entry and after achieving
>10% WL, on average 6 weeks after laparoscopic RYGBP.
Operative technique The patient was placed in the litho-
tomic position with legs abducted, under intermittent
pneumatic compression; two monitors were located on the
right side, at the level of shoulder and hip, and the
endoscope at the left shoulder. The procedure began with
the hemiomentectomy to facilitate the antecolic transposi-
tion of the Roux limb. The aspirator was inserted in the
epigastric trocar to retract the left liver. The height of the
gastroesophageal junction was localized by the transillumi-
nation of the endoscope and the gastric pouch was trans-
acted 6 cm caudally toward the angle of His alongside a
38 French bougie. The gastrojejunostomy was fashioned
manually by antecolic transposition of the entire bilio-
pancreatic limb about 50 cm caudally to the ligament of
Treitz without sectioning it. Along the Roux limb, a
distance of 150 cm from the gastrojejunostomy was then
measured and a side-to-side jejunojejunostomy was per-
formed. The biliopancreatic limb was than divided from the
gastrojejunostomy. Water-soluble contrast, such as gastro-
graffin, was checked by Rx through the anastomosis before
starting oral feeding on postoperative day 5.
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Statistical Analysis
A statistical analysis was performed using the Statistical
Package Social Sciences (SPSS), 14.0 program. Results are
expressed as the mean±standard deviation. Comparisons
were performed using unpaired t test. Linear correlation
analysis was performed. The null hypothesis was rejected at
a two-tailed p≤0.05.
Results
Both treatments were effective in reducing excess body
weight. The 10% WL was achieved more rapidly with
bariatric surgery than with integrated medical treatment
(6 vs 30 weeks).
Serum cholesterol levels were unchanged in group
1 (202±41 vs 202±43 mg/dl, p=n.s.) and significantly
decreased in group 2 (200±27 vs 168±36 mg/dl, p<0.01);
serum HDL-C did not change in group 1 (43.1±12 vs 43.4±
14 mg/dl, p=n.s.) but decreased significantly in group 2
(51.5±16 vs 43.5±13 mg/dl, p<0.005), whereas triglycer-
ides decreased in both groups (group 1=134±48 vs 114±
48 mg/dl, p=n.s.; group 2=156±70 vs 124±53 mg/dl,
p<0.02).
Blood glucose decreased significantly in both groups
(group 1=96.2±19 vs 89.4±9 mg/dl, p<0.05; group 2=
98.9±15.1 vs 90.8±9.9 mg/dl, p<0.01), as did insulin
serum concentration (group 1=25.1±12 vs 14.9±10 μg/U,
p<0.001; group 2=25.1±13.9 vs 10.6±5.6 μg/U,
p<0.001); the HOMA index significantly decreased ac-
cordingly (from 5.8±2.7 at baseline to 3.3±2.1 at 10% WL
p<0.001 in group 1 and from 6.1±3.3 to 2.4±1.3 in group
2, p<0.001).
All the MS risk factors improved with WL, but there was
a more marked reduction of the HOMA index after surgery
( p=0.001) (Table 1).
At entry, the prevalence of MS was 75% or 80% (n=15
or 16) according to the ATP III or AHA, respectively, in
group 1 and 65% or 70% (n=13 or 14) in group 2 (p=n.s.)
accordingly. After treatment, MS prevalence decreased in
both groups to 65% or 65% (n=13) in group 1 vs 40% or
40% (n=8) in group 2 (p<0.05).
FLI decreased in both groups (group 1=99.0±1.4 vs
91.9±9.1; p=0.001 and group 2=99.3±1.1 vs 96.4±5.4;
p=0.009) (Table 1).
Blood pressure values were similar at baseline (126/79±
13/10 mmHg in group 1 vs 128/83±10/7 in group 2,
p=n.s.), a significant reduction was observed only in group
1 patients at 10% WL (118/74±11/7 vs 128/83±17/7 in
group 2, p<0.002).
Heart rate showed a significant decrease only in surgical
patients compared to baseline (77.2±9.3 vs 75.9±9.3 beats/
min, p=n.s. in group 1 and 81.2±9 vs 73.0±12 beats/min,
p<0.001 in group 2).
At entry, FFM and FM was 50.7±6.7% and 49.3±6.7%
in group 1 and 52.1±6.1% and 47.9±6.1% in group 2,
respectively ( p=n.s.). After approximately 10% WL, body
composition distribution (FFM 50.7±6.7% and FM 49.3±
6.7%) significantly changed in group 1 (FFM increased to
55.9±6.5% and FM decreased to 44.1±6.5%; p=0.002),
but remained unchanged in surgical patients, as reported in
Table 1. RMR as absolute values decreased in both groups
but significantly (p<0.05) in surgically treated patients,
whereas corrected for FFM (RMR/FFM kg). RMR did not
significantly decrease in either group. Respiratory quotient
(RQ) decreased significantly (p=0.007) only in the surgical
group (Table 2).
Discussion
In evaluating the role of surgery in the treatment of
clinically severe obesity, a National Institutes of Health-
sponsored Consensus Conference panel concluded that “the
surgical procedures in use [gastric bypass and vertical
banded gastroplasty] can induce substantial weight loss [in
severely obese patients], and this, in turn, may ameliorate
Table 1 MS prevalence and FLI before and after medical and bariatric treatments
Medical treatment Bariatric surgery
Group 1 Group 2
Before After (6 months) Before After (6 weeks)
MS-ATP III (%) 15/20 (75) 13/20 (65) 13/20 (65) 8/20 (40)
MS-AHA (%) 16/20 (80) 13/20 (65) 14/20 (70) 8/20 (40)
FLI (%) 99.0±1.4 91.9±9.1* 99.3±1.1 96.4±5.4*
MS-ATP: Metabolic Syndrome according to Adult Treatment Panel III, MS-AHA: Metabolic Syndrome according to American Heart Association,
FLI: Fatty Liver Index.
*p<0.05 vs baseline
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comorbid conditions” [14]. This has been clearly demon-
strated by the Swedish Obesity Surgery (SOS) Study Group
that showed amelioration of all cardiovascular risk factors,
except for hypercholesterolemia, after surgery compared
with conventional therapy [15].
In a recent systematic review, O’Brien et al. asserted that
bariatric surgery can achieve a major weight reduction that
is sustained for at least 10 years. Each of the principal
groups of procedures shows a stable, at least 50%, excess
WL. No other therapy for severe obesity in use today could
achieve and sustain this degree of weight reduction over
such a period of time [16]. Laparoscopic Roux-en-Y gastric
bypass has gained greatest acceptance among bariatric
surgeons in the USA [17] and represents the first choice
intervention also by our group.
The large WL achieved with surgery may depend on
ongoing dietary/lifestyle interventions and should be
assessed against a 0.5–1% postoperative mortality risk and
an increased risk of wound dehiscence, venous thrombo-
embolism, and cardiorespiratory failure [18]. Newer lapa-
roscopic techniques, however, are associated with fewer
postoperative complications [18, 19].
Clinically important WL, defined by obesity experts as
5–10% loss of baseline weight [20, 21], may improve lipid,
glucose, and blood pressure levels [22, 23] with potential
reductions in cardiovascular risk [24]. However, it is
unclear if WL improves risk factors in all obese individuals
or in high-risk groups only. Few dietary/lifestyle and
surgical therapy studies have a ‘usual care’ control group,
which limits the assessment of WL efficacy that might
occur in clinical practice [25].
In our study, blood glucose, insulin, and HOMA index
significantly decreased in both groups; in particular, insulin
resistance improved 6 weeks after surgery, as also demon-
strated by other authors who have reported very early
changes in hormonal gastric pattern [26]. Blood triglycer-
ides also decreased in both groups according to other
studies [27]. MS prevalence was significantly reduced at
10% WL after surgery—a clearer improvement in result
compared to medical treatment. This improvement is
probably because of the drastic restriction of food absorp-
tion and possible gastrointestinal hormone adaptation. In
fact, the slightly greater reduction in HOMA index—
because of a drop in insulin serum concentration and
resistance—indicates that this type of bariatric surgery can
modify gastrointestinal endocrine pattern in a more favor-
able way than conventional medical treatment [28].
This is also mirrored by the reduction of RQ observed in
surgical patients. The reduction in RQ reflects the increased
fat oxidation that accompanies the faster WL because of the
reduction in food intake in the few weeks after surgery.
Maintenance of FFM is of particular concern in obesity
surgery when large amounts of body weight are lost in a
short length of time [29]. At the beginning of the bariatric
surgery experience, an undesirable marked loss of body cell
mass with a relative expansion of extracellular component,
typical of protein-energy malnutrition, has been observed
especially after jejunoileal bypass [30].
More recently, significant, although less severe, reduc-
tions of FFM have been reported after biliopancreatic
diversion [31, 32] and gastric bypass [33]. Gastric
restrictive procedures in which no malabsorptive mecha-
nisms were active and a less marked WL was produced
were considered to have only minor effects on FFM,
particularly when associated with a well-balanced low-
calorie diet. Nonetheless, Wadstrom et al. showed a
Table 2 Anthropometric characteristics and body composition changes before and after medical and bariatric treatments
Medical treatment Bariatric surgery
Group 1 Group 2
Before After (6 months) Before After (6 weeks)
WEIGHT (kg) 139±17 117±19* 138±27 124±24*
BMI (kg/m2) 50.1±8.5 42.1±7.8* 50.4±6.5 45.3±6.6*
WC (cm) 139.0±12.6 124.6±.9* 144.3±16.4 136.6±15.3*
FFM (%) 50.7±6.7 55.9±6.5* 52.1±6.1 51.9±6.2
FM (%) 49.3±6.7 44.1±6.5* 47.9±6.1 48.1±6.2
RMR (kcal/24 h) 2338±421 2051±382 2434±348 2135±376*
RMR/FFM (kcal/24 h·kg) 34.2±7.1 31.8±5.9 35.1±8.3 34.0±5.9
RQ 0.88±0.05 0.86±0.05 0.86±0.07 0.78±0.07**
BMI: body mass index, WC: waist circumference, FFM: fat-free mass, FM: fat mass, RMR: resting metabolic rate, RMR/FFM: resting metabolic
rate corrected for fat-free mass, RQ: respiratory quotient.
*p<0.05 vs baseline
**p<0.01 vs baseline and medical treatment
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significant decrease in lean body mass (LBM) and muscle
protein content in the rapid WL phase after gastroplasty [34].
Nevertheless, in patients treated with laparoscopic adjust-
able gastric banding (LAGB), a 2-year satisfactory WL can
be achieved without significant decrease in FFM [29].
In our study, % FFM appeared unchanged in surgically
treated patients, suggesting that, at least within the initial
phase of WL, there is a similar loss of FM and FFM also
related to the higher fluid loss in the short-term. In medical
patients, instead, the percentage increase in FFM might be
related to the physical activity program undertaken during
the 6 months of the study but specifically suggests that WL
obtained with the integrated medical treatment preferential-
ly involves fat mass more than FFM.
As well known, RMR accounts for a large percentage of
daily calorie expenditure. Obese individuals generally have
elevated RMR and experience a significant drop in RMR
with WL [31, 35]. Changes in body weight by 10% or more
obtained by dietary interventions are associated with
compensatory reduced changes in energy expenditure that
tend to oppose the weight change, and this may at least
partially account for the poor long-term results of obesity
treatment [36]. Gastroplasty has been associated with a
sustained fall in measured resting metabolic expenditure
(MRME) related to the metabolic compensation for
prolonged induced dietary restriction [37]. Very low calorie
diets are associated with a 15% to 30% reduction in
MRME, which tends to normalize during the refeeding
phase [38].
That WL may produce a disproportionate reduction in
RMR [39], even when adjusted for changes in LBM and
FM, has been disputed by some other authors [40, 41].
Carey et al. described a significant RMR reduction only in
the first month after surgery; this result is linear with LBM
changes. They found significant relationships between
decreases in LBM and RMR, 6 and 12 months after
surgery [11]. A study of RYGBP patients showed that the
loss of FFM accounted for 40% of the weight lost [27].
Our study shows a mild and nonsignificant reduction of
RMR in patients treated with an integrated dietetic plus
physical exercise program and a significant reduction of
RMR in surgically treated patients; however, RMR/FFM
remained unchanged in surgically and medically treated
patients. It will be necessary to have a larger number of
patients to confirm these findings.
In conclusion, our preliminary results confirm the safety
and efficacy of surgical treatment in improving metabolic
pattern and nutritional status of severe obesity provided that
a careful selection and clinical follow-up of patients is
performed by well-qualified surgical and medical teams.
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